Owner Scorecard


← All companies ← VPG Manual VREX → ← VNDA Pharmaceuticals VRTX →

VRDN, Viridian Therapeutics Inc.

Pharmaceuticals consumer brand UnprofitableDistress / turnaroundNet current asset value

We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases.

Tepezza is marketed in the United States ("U.S.") by Amgen Inc.

Latest annual: FY2025 10-K
VRDN · Viridian Therapeutics Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$71M
+23359.9% YoY · 132% 5-yr CAGR
Vital signs · TTM
Cash & investments $907M
Cash burn · annual $303M
Runway 3.0 yrs

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock. Net current asset value. Current assets alone exceed every liability combined, and the surplus is most of the balance sheet: the shape Graham called a net-net.
What moves the needle
Operating margin has run around −2691% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Stock-based pay runs about 89% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2015–2025

realized figures from each filing · older years to the left
2015’152017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMMar 2026
Income statement
$6M$4M$8M$4M$1M$3M$2M$314K$302K$71M$71MRevenueRevenue
135%273%132%261%n/m871%n/mn/mn/m135%165%SG&A / revenueSG&A/rev
18%490%363%780%n/mn/mn/mn/mn/m478%479%R&D / revenueR&D/rev
($11M)($27M)($33M)($42M)($110M)($80M)($134M)($254M)($299M)($363M)($386M)Operating incomeOp. inc.
−196.1%−662.8%−394.5%−941.0%n/mn/mn/mn/mn/m−512.9%−543.9%Operating marginOp. mgn
($11M)($27M)($33M)($42M)($111M)($79M)($130M)($238M)($270M)($343M)($361M)Net incomeNet inc.
Cash flow & returns
($7M)($28M)($27M)($36M)($30M)($55M)($94M)($184M)($232M)($276M)($303M)Operating cash flowOp. cash
$184K$308K$281K$288K$239K$120K$255K$522K$540K$460K$464KDepreciationDeprec.
$1M($4M)$2M$2M$77M$10M$16M($14M)($5M)$21M$9MWorking capital & otherWC & other
$123K$246K$445K$84K$42K$338K$797K$898K$511K$495K$432KCapexCapex
2.2%6.1%5.3%1.9%4.0%11.4%45.0%286.0%169.2%0.7%0.6%Capex / revenueCapex/rev
($7M)($28M)($27M)($36M)($30M)($55M)($94M)($185M)($233M)($277M)($304M)Owner earningsOwner earn.
−123.0%−709.8%−323.5%−810.1%n/mn/mn/mn/mn/m−390.8%−428.4%Owner earnings marginOE mgn
($7M)($28M)($27M)($36M)($30M)($55M)($95M)($185M)($233M)($277M)($304M)Free cash flowFCF
−123.0%−709.8%−325.4%−810.1%n/mn/mn/mn/mn/m−390.8%−428.4%Free cash flow marginFCF mgn
-69%-64%-266%-92%-42%-33%-54%-40%-47%-57%Return on equityROE
−69%−64%−266%−92%−42%−33%−54%−40%−47%−57%Retained to equityRetained/eq
Balance sheet
$21M$47M$62M$29M$209M$352M$425M$477M$718M$875M$907MCash & investmentsCash+inv
$394K$1M$24K$108K$57KReceivablesReceiv.
$242K$906K$571K$1M$670K$2M$14M$2M$2M$9M$13MAccounts payablePayables
$339K$550K($547K)($988K)($13M)Operating working capitalOper. WC
$12M$52M$65M$30M$130M$200M$431M$486M$738M$894M$785MCurrent assetsCur. assets
$2M$4M$7M$10M$11M$14M$33M$27M$48M$71M$52MCurrent liabilitiesCur. liab.
4.8×13.3×9.7×2.9×12.1×14.7×12.9×18.3×15.4×12.6×15.1×Current ratioCurr. ratio
$13M$52M$66M$30M$131M$204M$435M$490M$742M$899M$789MTotal assetsAssets
$10M$10M$8M$0$0$5M$20M$21M$50M$50MTotal debtDebt
($37M)($52M)($20M)($209M)($352M)($420M)($457M)($697M)($825M)($856M)Net debt / (cash)Net debt
-79.3×-69.3×-37.9×-50.3×-217.3×-26576.0×-268.6×-191.2×-136.1×-73.4×-49.1×Interest coverageInt. cov.
($45M)$39M$51M$16M$120M$188M$395M$442M$672M$722M$636MShareholders’ equityEquity
52.8%60.2%43.9%89.0%347.1%488.2%n/mn/mn/m62.5%66.9%Stock comp / revenueSBC/rev
Per share
21.6M19.2M29.6M2.1M3.6M11.9M32.1M44.8M81.0M102M102MShares out (diluted)Shares
$0.26$0.21$0.28$2.14$0.30$0.25$0.06$0.01$0.00$0.70$0.70Revenue / shareRev/sh
$-0.52$-1.38$-1.10$-20.04$-31.13$-6.66$-4.05$-5.31$-3.33$-3.36$-3.54EPS (diluted)EPS
$-0.33$-1.48$-0.92$-17.30$-8.38$-4.59$-2.93$-4.13$-2.87$-2.72$-2.98Owner earnings / shareOE/sh
$-0.33$-1.48$-0.92$-17.30$-8.38$-4.61$-2.95$-4.14$-2.87$-2.72$-2.98Free cash flow / shareFCF/sh
$0.01$0.01$0.02$0.04$0.01$0.03$0.02$0.02$0.01$0.00$0.00Cap. spending / shareCapex/sh
$-2.10$2.00$1.73$7.54$33.75$15.75$12.31$9.88$8.29$7.09$6.25Book value / shareBVPS

Share counts before 2017 are restated ×40 for a stock split, so per-share figures sit on one basis.

The diluted share count moved ×1.54 into 2018 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1/14.17 into 2019 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1.7 into 2020 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×3.35 into 2021 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×2.69 into 2022 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1.81 into 2024 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Per-share growththe realized rate an owner's share compounded
10-yr5-yr
Revenue / share+10.2%/yr+18.7%/yr
Capital spending / share−1.6%/yr−16.3%/yr
Book value / share−26.8%/yr

The record, charted

FY2015–2025

Each measure over its full record; the current point and the worst year marked. Share counts on the current split basis.

Share count
102Mpeak FY2025

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

($277M)owner earningsvs.($343M)net incomelow FY2025

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business turned a $343M loss into ($277M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2025FY2024FY2023FY2022FY2021
Reported net income($343M)($270M)($238M)($130M)($79M)
Depreciation & amortizationnon-cash charge added back+$460K+$540K+$522K+$255K+$120K
Stock-based compensationreal costnon-cash, but a real cost+$44M+$42M+$67M+$20M+$14M
Working capital & othertiming of cash in and out, other non-cash items+$21M−$5M−$14M+$16M+$10M
Cash from operations($276M)($232M)($184M)($94M)($55M)
Maintenance capital expenditurethe spending needed just to hold position and volume−$495K−$511K−$522K−$255K−$120K
Owner earnings($277M)($233M)($185M)($94M)($55M)
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$376K−$542K−$218K
Free cash flow($277M)($233M)($185M)($95M)($55M)
Owner-earnings marginowner earnings ÷ revenue-391%-77096%-58819%-5310%-1846%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $44M), owner earnings is nearer ($321M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income ($363M) ÷ interest expense $5M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash
    Cash $875M + ST investments $155M − debt $50M
    What this means

    Cash and short-term investments exceed every dollar of debt by $979M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Negative, funded by others
    DSO 1 + DIO 9 − DPO 1244 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. A negative cycle is a quiet moat: suppliers and customers fund the operation (Buffett's “float”), the company grows on other people's money.

Is it a good business?

  • Not meaningful here
    Invested capital ($103M) = debt $50M + equity $722M − cash
    Industry peers: median -108%
    What this means

    Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.

  • Consumes cash through the cycle
    10-yr median margin, range -77096%–-123%; latest ($277M) = operating cash ($276M) − maintenance capex $495K
    Industry peers: median -236%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -391% of revenue this year, a -1846% median across 10 years. Treating stock comp as the real expense it is (less $44M of SBC) leaves ($321M).

  • Loss, and burning cash
    Net income ($343M) · cash from operations ($276M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • No surplus to allocate
    What this means

    The business didn't generate positive Owner Earnings this year, so any distributions came from the balance sheet or borrowing, not from operations.

  • Investing or harvesting? 1.08×
    Maintaining
    Capex $495K ÷ depreciation $460K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 2 of 5 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $71M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 12.65×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $50M vs $824M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 10 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · none paid
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-2.75/share (latest year $-3.32), the averaged base the calculator's gate runs on, and book value is $7.01/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2015–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 0 of 10
    What this means

    Lost money in 10 year(s), look at what happened there before trusting the average.

  • Operating margin −418% → −60189% (3-yr avg ends)
    What this means

    Through the cycle the operating margin slipped — about −418% early to −60189% lately, median −2691% — competition or costs are biting in.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2024 · −99018.2% op. margin
    What this means

    Operations went underwater in 2024, understand why before trusting the good years.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Raised, but not as a competitor

The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product; it frames AI mainly as a capability.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Mar 31, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$785M
  • Cash & short-term investments$907M
  • Receivables$57K
  • Inventory$64K
Current liabilities$52M
  • Debt due within a year$8M
  • Accounts payable$13M
  • Other current liabilities$30M
Current ratio15.15×all current assets ÷ what's due · Graham looked for 2×
Quick ratio15.15×stricter: inventory excluded
Cash ratio17.50×strictest: cash alone against what's due
Working capital$733Mthe cushion left after near-term bills
Debt due this year vs. cash$8M due · $907M cash covered by cash on hand, no refinancing forced · both figures from the Mar 31, 2026 balance sheet
Cash runway3.0 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago+95.8%the freshest read on whether the business is still growing
Current ratio, recent quarters15.8× → 15.1×
Deeper floors
Tangible book value$636Mequity stripped of goodwill & intangibles
Net current asset value$632MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$32M$3M of it operating leases
Deferred revenue$414Kcustomer cash collected before delivery; operating float

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid.

  • Insider ownership2.4%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$44M

    The slice of the business handed to employees in shares this year, 63% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
ETONEton Pharmaceuticals Inc.$80M60%-6.8%-108%2%
CTMXCytomX Therapeutics Inc.$76M-124.3%-20%-81%
OMEROmeros Corporation$74M98%-451.5%-213%-417%
BCYCBicycle Therapeutics plc$73M-561.0%-1553%-236%
ASMBAssembly Biosciences Inc.$72M-602.7%-70%-130%
VRDNViridian Therapeutics Inc.$71M96%-1815.9%-1328%
FBIOPFortress Biotech, Inc.$63M68%-271.4%-372%-240%
TNGXTango Therapeutics Inc.$62M-329.3%-47%-269%
Group median82%-390.4%-238%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Viridian Therapeutics Inc. is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered43%/yr’20→’25

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−428%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Viridian Therapeutics Inc. (VRDN), the owner's record," https://ownerscorecard.com/c/VRDN, data as of 2026-07-09.

Manual order: ← VPG its page in the Manual VREX →

Industry order: ← VNDA the Pharmaceuticals chapter VRTX →